Martin Shkreli, the pharmaceutical head who was indicted for securities fraud last month, will be allowed to travel to Washington D.C. to testify before Congress about drug pricing, Eastern District Judge Kiyo Matsumoto ruled on Monday.
Although the ruling means Shkreli can’t use his bail conditions to escape attending a congressional hearing, he has said he will assert his Fifth Amendment right against self-incrimination if forced to testify.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
